ABC Index: quantifying experienced burden of COPD in a discrete choice experiment and predicting costs
Open Access
Abstract
Objective The Assessment of Burden of COPD (ABC) tool supports shared decision making between patient and caregiver. It includes a coloured balloon diagram to visualise patients’ scores on burden indicators. We aim to determine the importance of each indicator from a patient perspective, in order to calculate a weighted index score and investigate whether that score is predictive of costs. Design Discrete choice experiment. Setting and participants Primary care and secondary care in the Netherlands. 282 patients with chronic obstructive pulmonary disease (COPD) and 252 members of the general public participated. Methods Respondents received 14 choice questions and indicated which of two health states was more severe. Health states were described in terms of specific symptoms, limitations in physical, daily and social activities, mental problems, fatigue and exacerbations, most of which had three levels of severity. Weights for each item-level combination were derived from a Bayesian mixed logit model. Weights were rescaled to construct an index score from 0 (best) to 100 (worst). Regression models were used to find a classification of this index score in mild, moderate and severe that was discriminative in terms of healthcare costs. Results Fatigue, limitations in moderate physical activities, number of exacerbations, dyspnoea at rest and fear of breathing getting worse contributed most to the burden of disease. Patients assigned less weight to dyspnoea during exercise, listlessness and limitations with regard to strenuous activities. Respondents from the general public mostly agreed. Mild, moderate and severe burden of disease were defined as scores Conclusions The ABC Index is a new index score for the burden of COPD, which is based on patients’ preferences. The classification of the index score into mild, moderate and severe is predictive of future healthcare costs. Trial registration number NTR3788; Post-results.Keywords
Funding Information
- Almirall BV, Utrecht, The Netherlands
- the Innovation Fund Dutch Health Insurers, Zeist, The Netherlands
- GlaxoSmithKline BV, Zeist, The Netherlands
- Chiesi Pharmaceuticals BV, Rijswijk, The Netherlands
- Novartis BV, Arnhem, The Netherlands
- AstraZeneca BV, Zoetermeer, The Netherlands
- Picasso for COPD, Alkmaar, The Netherlands
This publication has 14 references indexed in Scilit:
- The Assessment of Burden of COPD (ABC) Scale: A Reliable and Valid QuestionnaireCOPD: Journal of Chronic Obstructive Pulmonary Disease, 2016
- Development of the Assessment of Burden of COPD tool: an integrated tool to measure the burden of COPDnpj Primary Care Respiratory Medicine, 2014
- Cost-Effectiveness of Early Assisted Discharge for COPD Exacerbations in The NetherlandsValue in Health, 2013
- Development and first validation of the COPD Assessment TestEuropean Respiratory Journal, 2009
- What's in this issuePrimary Care Respiratory Journal, 2008
- Factors determining the quality of life of patients with COPD in primary careTherapeutic Advances in Respiratory Disease, 2007
- Development and Validation of an Improved, COPD-Specific Version of the St. George Respiratory QuestionnaireChest, 2007
- Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEuropean Respiratory Journal, 2004
- Patients' Perception of Distress Due to Symptoms and Effects of Asthma on Daily Living and an Investigation of Possible Influential FactorsClinical Science, 1990
- A measure of quality of life for clinical trials in chronic lung disease.Thorax, 1987